Related Experiment Video

Updated: Dec 25, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

554

An exemplar population-based study to predict up-take of non-intensive therapies in acute myeloid leukaemia

Keith Ip1, Khaled Bedair2, Sudhir Tauro1

  • 1Dundee Cancer Centre, School of Medicine, Ninewells Hospital, Dundee, DD1 9SY, Scotland, United Kingdom.

Leukemia Research
|April 3, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.3K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

476

Related Experiment Videos

Last Updated: Dec 25, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

554
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.3K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

476

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K

Articles linked to this work by shared authors, journal, and citation graph.

Recovering from a therapeutic stall in higher-risk myelodysplastic syndromes: re-examining biology, backbones and study designs.

Haematologica·2026

Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues.

NPJ precision oncology·2025

The enzyme glycogen synthase kinase-3 is associated with specific forms of oncogenesis; what more do we need to know to achieve clinical benefit?

Biochimica et biophysica acta. Reviews on cancer·2025

Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer.

Cancer cell international·2025

Elraglusib Induces Cytotoxicity via Direct Microtubule Destabilization Independently of GSK3 Inhibition.

Cancer research communications·2024

Low-Dose Sulfonylurea Plus DPP4 Inhibitor Lower Blood Glucose and Enhance Beta-Cell Function Without Hypoglycemia.

The Journal of clinical endocrinology and metabolism·2024

Approval-standardized postmarketing safety reporting phenotypes of talquetamab versus BCMA-directed bispecific antibodies in multiple myeloma.

Leukemia research·2026

Intensive induction chemotherapy in adult acute myeloid leukemia: A single centre assessment of complete remission and induction mortality.

Leukemia research·2026

Beyond the binding site: PROTAC-mediated protein degradation assists the therapeutic paradigm of hematological malignancies.

Leukemia research·2026

Functional substitution of imatinib-inactivated canonical oncoprotein BCR::ABL1 by overexpressed PLAG1 results in BCR::ABL1-independent resistance in blast phase of chronic myeloid leukemia.

Leukemia research·2026

Outpatient step-up dosing of teclistamab and talquetamab in relapsed or refractory.

Leukemia research·2026

Advances in diagnosis and treatment of angioimmunoblastic T-cell lymphoma.

Leukemia research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us